Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system

P. M. Coloma, M. J. Schuemie, G. Trifiro, L. Furlong, E. van Mulligen, A. Bauer-Mehren, P. Avillach, J. Kors, F. Sanz, J. Mestres, J. L. Oliveira, S. Boyer, E. A. Helgee, M. Molokhia, J. Matthews, D. Prieto-Merino, R. Gini, R. Herings, G. Mazzaglia, G. PicelliL. Scotti, L. Pedersen, J. van der Lei, M. Sturkenboom, Eu-Adr consortium

Research output: Contribution to journalArticleAcademicpeer-review


BACKGROUND: Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are being used in 'real-world' settings. OBJECTIVE: To describe a strategy that identifies potentially drug-induced acute myocardial infarction (AMI) from a large international healthcare data network. METHODS: Post-marketing safety surveillance was conducted in seven population-based healthcare databases in three countries (Denmark, Italy, and the Netherlands) using anonymised demographic, clinical, and prescription/dispensing data representing 21,171,291 individuals with 154,474,063 person-years of follow-up in the period 1996-2010. Primary care physicians' medical records and administrative claims containing reimbursements for filled prescriptions, laboratory tests, and hospitalisations were evaluated using a three-tier triage system of detection, filtering, and substantiation that generated a list of drugs potentially associated with AMI. Outcome of interest was statistically significant increased risk of AMI during drug exposure that has not been previously described in current literature and is biologically plausible. RESULTS: Overall, 163 drugs were identified to be associated with increased risk of AMI during preliminary screening. Of these, 124 drugs were eliminated after adjustment for possible bias and confounding. With subsequent application of criteria for novelty and biological plausibility, association with AMI remained for nine drugs ('prime suspects'): azithromycin; erythromycin; roxithromycin; metoclopramide; cisapride; domperidone; betamethasone; fluconazole; and megestrol acetate. LIMITATIONS: Although global health status, co-morbidities, and time-invariant factors were adjusted for, residual confounding cannot be ruled out. CONCLUSION: A strategy to identify potentially drug-induced AMI from electronic healthcare data has been proposed that takes into account not only statistical association, but also public health relevance, novelty, and biological plausibility. Although this strategy needs to be further evaluated using other healthcare data sources, the list of 'prime suspects' makes a good starting point for further clinical, laboratory, and epidemiologic investigation.
Original languageEnglish
Pages (from-to)e72148
JournalPLoS ONE
Issue number8
Publication statusPublished - 2013


  • Acute Disease Adverse Drug Reaction Reporting Systems Azithromycin/adverse effects/therapeutic use Betamethasone/adverse effects/therapeutic use Cisapride/adverse effects/therapeutic use Domperidone/adverse effects/therapeutic use Electronic Health Records Fluconazole/adverse effects/therapeutic use Humans Megestrol Acetate/adverse effects/therapeutic use Metoclopramide/adverse effects/therapeutic use Myocardial Infarction/*chemically induced

Cite this